ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed
Hagens Berman filed a class action lawsuit against ADMA Biologics alleging securities fraud related to undisclosed related-party transactions and channel stuffing. The complaint references a short-seller report by Culper Research that triggered a significant stock decline, with a lead plaintiff deadline set for Aug. 10, 2026. This is a solicitation for shareholders who purchased securities between Aug.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.